Issue 371

Test Your Knowledge Issue 371

Mike is a 32-year-old male who has had type 1 diabetes for 20 years. He is currently on 25 units of Lantus at bedtime as his basal insulin and a fast-acting insulin (Apidra), which he takes...

Exercising with Complications: Cardiovascular Disease and Hypertension

To often our patients tell us they are not allowed to have any physical activity because of the Cardiovascular concerns. Dr. Sheri Colberg, author of The 7 Step Diabetes Fitness Plan: Living Well and Being Fit with Diabetes, has the right things to...

Dyslipidemia In Insulin Resistance:  Hypertriglyceridemia And Low HDL Cholesterol

Last week I had the great opportunity to meet Dr. Phil Wood at the ADA conference in Chicago, we chatted about fat and other things and he prepared this week’s article based on his review of the abstracts. Be sure to read Dyslipidemia In Insulin...

ADA: Rosiglitazone Debated at ADA Meeting

They were waiting in a long line outside the hall to see Dr Steven Nissen (Cleveland Clinic, OH). 

ADA: Diabetics at Increased Risk of Hearing Loss

Diabetics should be screened for hearing loss because they have twice the risk of developing hearing loss as are nondiabetics, researchers reported at the American Diabetes Association 67th Scientific Sessions (ADA).

Markers of "Prediabetes" Independently Raises Mortality Risk 60%

Markers of impaired glucose metabolism in nondiabetics were independently related to increased risks of all-cause and cardiovascular death in a large population-based study.

U.S. Survey Shows Uninsured Numbers 43.6 Million

Just under 44 million Americans had no health insurance in 2006, according to a survey by the U.S. Centers for Disease Control and Prevention released last Monday.

Exubera Manufacturer Cuts Jobs Due to Poor Sales

The UK-based drug delivery device manufacturer said that following the slow take-up of Exubera by diabetes patients, Nektar Therapeutics and Pfizer have revised their short term forecasts for the inhalation device, which will result in a reduction in...

ADA: For Diabetes/Prediabetes Screening, Random Blood Sugars are Cheaper and Easier Then OGTT

For diabetes and prediabetes screening, random plasma glucose testing alone appears to be at least as good as the full gamut of metabolic syndrome tests, and is easier and cheaper to boot, researchers found.

ADA: Investigational Diabetes Drug Lowers Glucose Via New Mechanism

Dapaglifozin, a novel investigational antidiabetic agent that increases excretion of glucose in urine, independent of insulin secretion or insulin action, appeared safe and effective in early clinical trials.

ADA: Neuropathy Most Likely to Strike in Type 2 Diabetes Not in Type 1

Painful neuropathy is more common in patients with type 2 diabetes than in those with type 1, due to metabolic syndrome, researchers suggest, because of a link with the metabolic syndrome.

Stone-Age Low-Carb Diet Is Best to Lower Blood Sugars

According to a new study you can toss out the Mediterranean cookbooks and turn back to the Stone Age if you're looking to lower your blood-sugar levels.

Early Tight Control and Aggressive Treatment Pays Off

There seems to be a point of no return in the onset of diabetes and scientists have speculated exposure to high glucose levels quickly creates a metabolic memory due to glycation, in which diabetes persists long after the glucose levels are corrected.

U.S. White Youths Have Highest Incidence of Type 1 Diabetes

Non-Hispanic white youth have the highest rate of diabetes of all racial/ethnic groups for children in the U.S., with type 1 being the predominant kind of diabetes among youth.

ADA: Diabetes-Related Education Cuts Hospitalizations and Charges

Diabetes education, especially counseling from nutritionists, can reduce hospitalizations and lower hospital charges by 14 thousand dollars, for urban, low-income patients.

Value of Glucose Monitoring for Non-insulin Using Diabetes Patients?

A new study published on bmj.com questions the value of blood glucose monitoring among patients with well-controlled, non-insulin dependent (type 2) diabetes. See Publishers Note.

New Beta-Cell Regeneration Drug Shows Improvements Post Treatment

Transition Therapeutics Announces Results of 6-Month study with Their E1-INT Drug Final results from exploratory Phase IIa Clinical Trial in type 2 diabetes patients after once a day injections for 28 days and then followed for 6 months, lead to...

Teach Doctors To Cook And Walk

Walk two miles and call me in the morning. That’s what doctors could soon prescribe if the new leaders of two major medical groups have their way.